论文部分内容阅读
目的探讨肝激酶B1(LKB1)在肺腺癌中的表达及意义。方法应用免疫组化方法检测LKB1在87例肺腺癌及癌旁正常肺组织中的表达,并分析其表达与肿瘤临床病理因素及预后的相关性。结果 LKB1在正常肺组织中高表达,在肺腺癌中表达下调(P<0.001);在肺腺癌中,LKB1表达下调与患者的淋巴结转移正相关(r=0.337,P=0.002)同时与高分化负相关(r=-0.269,P=0.012);在预后分析中,除了TNM分期(P<0.001)之外,LKB1表达下调也是影响肺腺癌患者预后的独立因素(P=0.001)。结论 LKB1表达下调促进肺腺癌的发生发展,并与其不良预后相关。
Objective To investigate the expression and significance of hepatic kinase B1 (LKB1) in lung adenocarcinoma. Methods The expression of LKB1 in 87 cases of lung adenocarcinoma and adjacent normal lung tissue was detected by immunohistochemistry. The correlation between the expression of LKB1 and the clinicopathological factors and prognosis was analyzed. Results LKB1 was highly expressed in normal lung tissue and down-regulated in lung adenocarcinoma (P <0.001). In lung adenocarcinoma, LKB1 expression was positively correlated with lymph node metastasis (r = 0.337, P = 0.002) (R = -0.269, P = 0.012). In the prognostic analysis, in addition to the TNM stage (P <0.001), the down-regulation of LKB1 was also an independent factor affecting the prognosis of patients with lung adenocarcinoma (P = 0.001). Conclusions The down-regulation of LKB1 promotes the development of lung adenocarcinoma and correlates with its poor prognosis.